What Are Fibrocytes and What Is Their Function?

Fibrocytes are a distinct class of blood-borne cells that originate in the bone marrow and combine traits of immune cells with traits of the connective-tissue cells that build and repair your body’s structural framework. First described in 1994, they make up a tiny fraction of circulating blood cells, but they punch well above their weight when tissue is damaged. They rush to wound sites, help fight infection, lay down new structural proteins, and orchestrate repair. When that repair process overshoots, though, fibrocytes become central players in fibrosis, the excessive scarring that can stiffen and destroy organs like the lungs, liver, and kidneys.

A Cell That Does Not Fit Neatly Into One Category

Most cells in the body fall into reasonably tidy categories. Immune cells patrol for threats. Fibroblasts produce the collagen and other structural proteins that hold tissues together. Fibrocytes blur that line. They are bone marrow-derived mesenchymal progenitor cells that express surface markers associated with leukocytes (white blood cells), blood-forming stem cells, and fibroblasts all at once.¹ That combination is what makes them unusual: they circulate in the bloodstream like immune cells, but once they reach damaged tissue, they can behave like fibroblasts, producing collagen and contracting wounds.

Roughly half a percent of the non-red-blood cells in your blood are fibrocytes at any given time. They develop from a type of white blood cell called a CD14-positive monocyte. Under the right conditions, a monocyte can transform into a fibrocyte within about three days.² Normally the body keeps that transformation in check through a blood protein called serum amyloid P (SAP), which acts as a brake. When SAP levels drop or when injury signals overwhelm the brake, more monocytes convert to fibrocytes and head toward damaged tissue.

How Fibrocytes Differ From Fibroblasts

Because the names sound nearly identical, fibrocytes and fibroblasts are easy to confuse, but they are fundamentally different cells with different origins and different jobs. Fibroblasts are resident cells already sitting in your tissues. They are the workhorses of collagen production, building the scaffolding that holds skin, tendons, and organs together. Fibrocytes, by contrast, are visitors. They originate in bone marrow, travel through the bloodstream, and arrive at a wound or injury site only when summoned by chemical signals.

Researchers have identified specific marker combinations that tell the two cell types apart. Fibroblasts carry a distinctive set of surface proteins including CD90, cellular fibronectin, hyaluronan, and TE-7. Fibrocytes share some markers with macrophages but lack others, carrying their own unique combination that distinguishes them from monocytes, macrophages, and fibroblasts alike.³ In practical terms, a pathologist looking at a tissue sample can use these markers to determine which cells showed up from the bloodstream (fibrocytes) and which were already on site (fibroblasts).

There is also a meaningful difference in how much structural protein each cell type produces. When researchers used mass spectrometry to measure collagen output, they found that fibrocytes from both healthy people and burn patients produce far less collagen than dermal fibroblasts do.⁴ Their collagen gene expression profile also differs: fibrocytes produce relatively high levels of collagen VI but much lower levels of collagens I, III, and V compared with fibroblasts. Fibrocytes also have a trick fibroblasts lack, the ability to internalize and break down collagen fragments through a specific receptor-mediated mechanism, meaning they participate in both building and dismantling the structural matrix around a wound.

The Many Roles Fibrocytes Play in Wound Healing

Wound healing is where fibrocytes really show their versatility. They contribute to repair through at least seven distinct mechanisms, which is part of why researchers sometimes describe them as combining the inflammatory properties of macrophages with the tissue-remodeling properties of fibroblasts.⁵

Immune defense: Fibrocytes can present fragments of pathogens to T cells, essentially raising the alarm and activating the adaptive immune system. They are surprisingly good at this, nearly as effective as dendritic cells, which are considered the professional antigen-presenting cells of the body.⁶
Pathogen killing: They can directly fight microbes by releasing extracellular traps and antimicrobial peptides, and they have some ability to engulf and destroy pathogens through phagocytosis.⁵
Chemical signaling: Fibrocytes release cytokines, chemokines, and growth factors that coordinate the broader wound-healing response, calling in other cell types and directing their behavior.
Structural repair: They secrete extracellular matrix proteins and glycosaminoglycans that form the new tissue scaffolding.
Wound contraction: They can transform into myofibroblasts, cells packed with contractile fibers that physically pull wound edges together.
Blood vessel growth: They promote angiogenesis by secreting growth factors including VEGF, basic FGF, PDGF, and IL-8, all of which stimulate endothelial cells to form new blood vessels.⁷
Cell transformation: Beyond becoming myofibroblasts, fibrocytes can differentiate into other mesenchymal cell types, including fat cells, that contribute to new tissue formation.

In a corneal injury model, researchers traced bone marrow-derived fibrocytes migrating into wounded eye tissue and found that by two weeks after injury, more than half of the bone marrow-derived immune cells in the wound had differentiated into myofibroblasts.⁸ That transformation is useful in the short term, since myofibroblasts help close wounds quickly, but it becomes a problem when it does not shut off.

When Healing Goes Wrong and Fibrosis Takes Over

Fibrosis is essentially wound healing that will not stop. Instead of laying down just enough scar tissue to seal a wound and then quieting down, the process keeps running, producing excess collagen and stiffening the affected organ until it cannot function properly. Fibrocytes are deeply implicated in this runaway process across multiple organs.

In the lungs, fibrocytes travel from the bone marrow to injured lung tissue and contribute to fibrogenesis, the progressive buildup of scar tissue.⁹ They are recruited to the lungs through specific chemical signaling pathways. One well-studied route uses the chemokine receptor CCR2: in mouse studies, animals lacking CCR2 had significantly fewer fibrocytes in their lungs after injury and were less susceptible to fibrosis. When researchers transplanted CCR2-equipped bone marrow into those mice, fibrocyte recruitment and fibrosis susceptibility were both restored.¹⁰ A second pathway uses CXCR4, another receptor, with its partner signal CXCL12. Blocking this axis in animal models reduced the severity of pulmonary fibrosis.¹¹

The lungs are not the only organ affected. Because fibrocytes can differentiate into collagen-producing myofibroblasts, they have been implicated in the pathogenesis of fibrosis in the liver, skin, and kidneys as well.¹² Wherever chronic injury triggers persistent inflammation, fibrocytes can arrive, differentiate, and add to the scarring process. In rheumatoid arthritis, activated fibrocytes appear to influence disease progression and may serve as precursors to the fibroblast-like synovial cells that drive joint destruction.¹³ In Dupuytren’s disease, a condition where scar-like tissue forms in the palm and bends the fingers, both circulating and resident fibrocytes have been identified in the affected tissue.¹⁴

Fibrocytes as a Blood Test for Disease Severity

One of the more practically useful aspects of fibrocytes is that they circulate in the blood, which means you can count them with a blood draw. This has led researchers to investigate whether fibrocyte counts could serve as a biomarker for how badly fibrotic diseases are progressing and how likely a patient is to survive.

The evidence is most developed for idiopathic pulmonary fibrosis (IPF), a devastating lung disease with no cure. In a study of 51 patients with stable IPF, circulating fibrocytes were significantly elevated compared with healthy people, and they rose even further during acute disease flare-ups. Fibrocyte numbers did not correlate with standard lung function tests or imaging scores, but they did independently predict early death. Patients whose fibrocytes made up more than 5% of their total blood white cells survived a mean of about 7.5 months, compared with 27 months for those below that threshold.¹⁵ A larger pooled analysis of 162 IPF patients using a somewhat different cutpoint confirmed a roughly 2.5-fold greater risk of death when fibrocyte levels were high.¹⁶

Similar findings have appeared in Hermansky-Pudlak syndrome, a rare genetic condition that causes lung fibrosis. Elevated levels of fibrocytes carrying the CXCR4 receptor were strongly linked to death from lung disease in those patients.¹⁷ These are still relatively early findings, and the preliminary data from single-center studies require independent validation before fibrocyte counts become part of routine clinical care.¹⁸ But the concept is appealing: a simple blood test that captures something lung function tests miss, namely how aggressively the body is sending repair cells to a lung that is being progressively scarred.

Therapeutic Approaches Targeting Fibrocytes

If fibrocytes drive fibrosis, blocking them ought to slow or stop it. Several strategies are in various stages of development.

The most intuitive approach exploits the body’s own braking system. Recall that serum amyloid P (SAP) normally prevents monocytes from transforming into fibrocytes. A recombinant version of this protein, called PRM-151 (also known as recombinant human Pentraxin-2), has been tested in clinical trials. In patients with pulmonary fibrosis, administering PRM-151 resulted in a 30-50% decrease in circulating fibrocyte numbers within 24 hours of dosing.¹⁹ The drug has been described as a potential first-in-class natural modulator of fibrotic pathology, with preclinical evidence spanning multiple types of fibrosis.²⁰

Another strategy targets the traffic signals that bring fibrocytes to damaged organs. Blocking the CXCR4/CXCL12 signaling axis in human fibrocytes reduced their migration, and in animal models of lung fibrosis, this approach decreased the severity of scarring.¹¹ The immunosuppressant sirolimus has also shown the ability to suppress circulating fibrocytes in IPF patients in a randomized crossover trial, suggesting that existing drugs may already have fibrocyte-modulating effects that had not been recognized.⁹

None of these approaches has yet become standard treatment, but they represent a shift in how researchers think about fibrosis. Instead of only trying to manage symptoms or slow progression with broad anti-inflammatory drugs, targeting fibrocytes aims at one of the cellular sources of the problem.

Fibrocytes in the Tumor Microenvironment

A more recent and still-emerging area of research involves fibrocytes in cancer. Tumors often hijack the body’s wound-healing machinery. The chronic tissue damage caused by a growing tumor, along with the cytokines it and surrounding immune cells produce, can attract fibrocytes the same way a wound does. Once there, fibrocytes may help the tumor survive and spread by remodeling the surrounding tissue, promoting blood vessel growth, and modulating immune responses in ways that favor the cancer.²¹

This connection is still in early stages. Researchers have proposed that because fibrocytes are wound-healing cells coopted by tumors, they could become targets for anticancer therapy. The logic tracks with what is already known about their biology: if you can block fibrocyte recruitment to fibrotic lungs, perhaps you can also block their recruitment to a tumor that is exploiting the same chemical signals. But the evidence base here is thin compared with what is known about fibrocytes in fibrosis, and it is too early to know whether targeting fibrocytes would meaningfully change cancer outcomes.

Unresolved Questions in Fibrocyte Biology

Despite decades of research, some fundamental questions about fibrocytes remain open. One is whether the cells researchers count in the bloodstream are truly the same cells that show up in damaged tissue. A study using a novel transgenic mouse model, in which bone marrow-derived cells were permanently labeled with a fluorescent marker, found two distinct populations of collagen-producing blood-lineage cells at wound sites. One population matched the traditional definition of a fibrocyte, expressing the expected surface markers. The other was a previously unidentified population that produced collagen but lacked those markers entirely.²² That discovery complicates the picture: there may be more than one type of blood-derived cell contributing to tissue repair and scarring, and current methods of counting fibrocytes could be missing part of the story.

Another gap is the question of how much direct structural contribution fibrocytes actually make versus how much they influence other cells. Their collagen output is modest compared with fibroblasts, which has led some researchers to argue that fibrocytes matter more as signaling hubs, releasing growth factors and cytokines that activate the resident fibroblasts already in the tissue, than as collagen producers themselves.⁴ If that is true, the therapeutic approach would shift: instead of blocking fibrocyte arrival, you might focus on interrupting the signals they send once they get there. The field has not settled on which framing is more accurate, and the answer may differ depending on the organ and the type of injury involved.

1
PubMed Central. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders
2
PubMed Central. Inhibition of fibrocyte differentiation by serum amyloid P
3
PubMed Central. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts
4
PubMed. Fibrocytes from burn patients regulate the activities of fibroblasts
5
PubMed Central. Fibrocytes, Wound Healing, and Corneal Fibrosis
6
PubMed. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ
7
PubMed. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo
8
PubMed Central. Fibrocyte migration, differentiation and apoptosis during the corneal wound healing response to injury
9
PubMed Central. Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial
10
PubMed Central. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury
11
PubMed Central. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis
12
PubMed Central. Bone marrow-derived fibrocytes contribute to liver fibrosis
13
PubMed Central. Fibrocyte activation in rheumatoid arthritis
14
PubMed Central. First identification of resident and circulating fibrocytes in Dupuytren’s disease shown to be inhibited by serum amyloid P and Xiapex
15
PubMed. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis
16
medRxiv. Circulating fibrocytes can identify people with a poor prognosis in idiopathic pulmonary fibrosis
17
PubMed Central. Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome
18
PubMed Central. Fibrocytes in pulmonary fibrosis: a brief synopsis
19
PubMed. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis
20
PubMed. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
21
PubMed Central. Fibrocytes in the Tumor Microenvironment
22
PubMed Central. Tracking the elusive fibrocyte: identification and characterization of collagen-producing hematopoietic lineage cells during murine wound healing